-

Researcher John Craig Venter Is Awarded the 2020 Edogawa-NICHE Prize for His Accomplishment in Human Genome Research

TOKYO--(BUSINESS WIRE)--The Edogawa NICHE Prize for the year 2020 has been awarded to Dr. John Craig Venter for his contribution to research and development pertaining to the Human genome. This honor reflects Dr. Venter's lifetime accomplishments in the power of the genomics and specifically in the identification of the human genome which has radically transformed healthcare according to Prof. Gary Levy, chair, Edogawa NICHE awards committee (www.edogawanicheprize.org).

Edogawa NICHE Prize was Instituted in 2018, by the Jinseisha trust, and the Nichi-In Centre for Regenerative Medicine (NCRM), which honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of any disease, through an inter-disciplinary approach. Alumni of the Fujio Cup Quiz, a part of NCRM NICHE, (www.ncrmniche.org), have priority for nomination, a unique feature of this prize. Previous awardees include Prof James Till, University of Toronto, Canada for discovery of stem cells (2018) and Dr. Steven Rosenberg, National Institutes of Health, USA for his groundbreaking work on T-lymphocyte immunotherapy (2019).

Dr. Venter was born in Salt Lake City Utah on October 14, 1946. He started his college education at the College of San Mateo, CA and later studied Biochemistry in University of California, San Diego under biochemist Nathan O. Kaplan. After obtaining a PhD in Physiology and Pharmacology from UCSD, he became a Professor at the State University of New York and joined the National Institute of Health in 1984. He has founded Celera Genomics, The Institute of Genomic Research (TIGR), J.Craig Venter Institute (JCVI) and co-founded Human Longevity Inc and Synthetic Genomics.

His path breaking sequencing of the first human genome with the Human Genome Project further progressed to transfecting a cell with a synthetic chromosome, a feat that has opened up opportunities to develop novel solutions not only in healthcare, but also in environmental issues and energy domain.

The awarding of the Edogawa NICHE prize to Dr Venter is the most recent in a string of honors including United States Medal of Science (2008), Gardner Foundation International Award (2002), Paul Erlich and Ludwig Darmstaedter Prize (2001) and the King Faisal International Award of Science (2001). He was listed on Time Magazine’s list of the most influential people in the world.

The award ceremony date will be announced later.

Contacts

Queries to:
Samuel JK Abraham
info@gncorporation.com

GN Corporation Co. Ltd.


Release Summary
Dr Venter's sequencing of the first human genome & progress in transfecting a cell with a synthetic chromosome, paved ways to numerous opportunities

Contacts

Queries to:
Samuel JK Abraham
info@gncorporation.com

More News From GN Corporation Co. Ltd.

Cell therapy for male urethral stricture: BEES-HAUS clinical application in Edogawa Hospital Japan, reports Dr. Akio Horiguchi in IMORU.

TOKYO--(BUSINESS WIRE)--Urethral stricture affecting men of all ages, with increasing incidence after 55, is a recurring problem despite several treatment options. By transplanting autologous lab-engineered buccal tissue cells (BEES-HAUS), Dr Akio Horiguchi successfully accomplished the first clinical transplantation in Edogawa Hospital, Japan as per Japanese Regenerative Medicine law, and presented in International Meeting Of Reconstructive Urology (IMORU) in Hamburg, Germany. Safety and effic...

Astronauts’ Health During Space Missions: Nichi BRITE and Neu REFIX Beta Glucans Could Benefit by Neutrophil-to-Lymphocyte Ratio, IL-6 Control, the Immune Biomarkers of Aging and Longevity

TOKYO--(BUSINESS WIRE)--Neutrophil to Lymphocyte ratio (NLR) is a critical biomarker of health of astronauts during space mission, and that of aging related illnesses, inflammaging, longevity and cancer prognosis. Oral consumption of AFO-202 strain of Aureobasidium pullulans produced Nichi BRITE and N-163 strain produced Neu REFIX together in pre-clinical and clinical studies having safely and beneficially modified NLR, are considered holding potential to help maintain astronauts health during...

Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy

TOKYO--(BUSINESS WIRE)--Neu refix granted orphan disease designation (ODD) & rare pediatric disease designation (RPDD) by US FDA for treatment of Duchenne muscular dystrophy...
Back to Newsroom